MeiraGTx: Revolutionizing Gene Therapy with Advanced Manufacturing and Riboswitch Technology

MeiraGTx, a leader in gene therapy and genetic medicine, boasts a comprehensive in-house manufacturing platform that supports the entire production process from plasmid production for GMP to viral vector production and quality control for stability and release. This infrastructure is designed to support the company’s pipeline from Investigational New Drug (IND) applications through to commercial supply.

The company is pioneering advances in viral vector design and optimization and has developed a cutting-edge riboswitch gene regulation platform. This technology allows for precise, dose-responsive control of gene expression using oral small molecules, which has the potential to revolutionize treatments across a range of conditions.

MeiraGTx is strategically focusing its riboswitch platform on the delivery of metabolic peptides such as GLP-1, GIP, Glucagon, and PYY via oral small molecules. In addition, the company is exploring cell therapy applications for oncology and autoimmune diseases. Initially targeting the eye, central nervous system, and salivary gland, MeiraGTx is expanding its technology to address more common diseases, enhancing treatment efficacy, targeting novel areas, and broadening access to some of the largest unmet medical needs.

For further details, visit MeiraGTx's website.

Forward-Looking Statements

This release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements are based on current management expectations and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially. Factors influencing these outcomes include the company's ability to achieve profitability, regulatory approvals, competition, and the impact of the COVID-19 pandemic, among others. For a detailed discussion of these risks, refer to the "Risk Factors" section in MeiraGTx's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, available on the SEC's website.

Contact Information

For investor inquiries, contact MeiraGTx at investors@meiragtx.com. For media inquiries, contact Jason Braco, Ph.D. at LifeSci Communications via jbraco@lifescicomms.com.